Shoshana Golden’s Perspectives

59 total results. Page 1 of 5.

Investigations Blog
Federal Government Urges Court of Appeals to Uphold Constitutionality of FCA Qui Tam Provisions
Alerts
New Year, Same MoCRA: FDA Cosmetic Requirements as of January 1, 2025
Investigations Blog
Second Circuit Partially Affirms Novartis’ Motion to Dismiss AKS Claims
Alerts
FDA Issues New Cosmetics Proposed Rule: Let’s Talk About Talc
Alerts
Three Overhauls to Accelerated Drug Approval You Need to Know About: Novel Endpoints, Confirmatory Trials, and Expedited Withdrawal of Approvals
News
FDA Final Guidance on Cosmetic Facility Registration and Product Listing: Take Two
Health Care Counsel Blog
The 2025 Final Hospital Outpatient Prospective Payment System and Physician Fee Schedule Rules: What Pharma Stakeholders Need to Know
Investigations Blog
US Supreme Court Declines to Consider AKS ‘Willfulness’ Question
Investigations Blog
Florida Federal Judge Strikes Down FCA’s Qui Tam Provision as Unconstitutional
Alerts
New USDA Rules for FSIS-Regulated Products Aimed at Safeguarding Consumers
Health Care Counsel Blog
The 340B ‘Saga’ Continues: As More States Pass 340B Contract Pharmacy Laws, More Lawsuits Follow
Investigations Blog
Precision Lens Pays $12 Million to Resolve FCA and AKS Violations